Skip to main content

Table 1 Treatment-related adverse events

From: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

  Dose (mg/kg) Grade 1, N (%) Grade 2, N (%)
Nausea 4 and 8 2 (13.3) 0
Headache 4 1 (6.7) 0
Chills 8 1 (6.7) 0
Throat tightness 8 1 (6.7) 0
Decreased WBC 16 1 (6.7) 0
Fatigue 32 1 (6.7) 2 (13.3)
Constipation 32 1 (6.7) 0
Hypersomnia 32 0 2 (13.3)
Hypophosphatemia 32 0 2 (13.3)
  1. All adverse events at least possibly attributed to study drug are shown. There were no grade 3 or grade 4 treatment-related adverse events. Adverse event grade is according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0
  2. kg kilogram
  3. mg milligram
  4. WBC white blood cell